Advancements in treatment include immune checkpoint inhibitors and BRAF/MEK inhibitors, though resistance remains a challenge, with lifileucel recently approved for previously treated metastatic cases.
Jina Yun, PharmD
Advertisement
Articles by Jina Yun, PharmD
Axitinib, cabozantinib, and lenvatinib are first-line treatment options.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
Anitocabtagene Autoleucel Demonstrates Deep, Durable Responses and Improved MRD-Negativity in RRMM
2
Inclisiran, PCSK9s Elicits Sustained LDL-C Reductions in Familial Hypercholestrolemia
3
Delayed Statin Initiation Following Detection of High LDL-C Raises Risk of Heart Attack
4
Biolinq Shine Receives FDA De Novo Classification as First Multi-Analyte Wearable for Type 2 Diabetes
5
